Outcomes of patients with cytomegalovirus viremia at the time of liver transplantation.
Cytomegalovirus (CMV) infection has been associated with poor outcomes after liver transplantation. Whether it is safe to perform transplantation for patients with active CMV viremia is not known. Here we report the outcomes of 6 patients with CMV viremia immediately before or at the time of liver transplantation. Data from these patients indicate that CMV can be adequately controlled with antiviral therapy, although patients appear to be at higher risk for indirect effects of CMV such as other opportunistic infections and liver allograft dysfunction.
Division of Infectious Diseases, Mayo Clinic, Rochester, MN.
Jackrapong
J
Bruminhent
Raymund R
RR
Razonable
D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use; D003586:Cytomegalovirus Infections / Q000097:blood / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D058625:End Stage Liver Disease / Q000150:complications / Q000175:diagnosis / Q000601:surgery*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016031:Liver Transplantation / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D008910:Minnesota; D011183:Postoperative Complications / Q000209:etiology; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D019562:Viral Load; D055815:Young Adult
D000998:Antiviral Agents; D007166:Immunosuppressive Agents